Skip to main content
Clinical Trials/NCT07142447
NCT07142447RecruitingNot Applicable

Understanding and Preventing the Impact of Endocrine Disruptors on the Hypothalamus-pituitary Axis in Sensitive Populations. Hypiend- Perinatal Study.

Fundació Institut Germans Trias i Pujol1 site in 1 country810 target enrollmentStarted: February 24, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
810
Locations
1
Primary Endpoint
Decrease of mono(2-ethyl-5-oxohexyl) phthalate (MEOHP) concentration in urine

Study Overview

Brief Summary

The general objective of HYPIEND is to understand the effects of chemical substances called "endocrine disruptors" (EDCs) during the perinatal and pre-pubertal stages. EDCs co-exposure may affect the function of hormones and determine endocrine consequences in vulnerable populations.

The primary objective of this clinical study is to demonstrate that a multicomponent intervention implemented in health care centres from three European countries is effective in reducing the levels of EDCs in different body fluids of pregnant women, breastfeeding and formula feeding women as well as in their infants up to 18 months of age, improving at the same time the level of HAPA constructs (psychological determinants of behaviour) and the knowledge about these chemicals at family level.

Detailed Description

Study rationale

  1. Extent and evaluation of current knowledge directly linked to the scientific question(s) to be answered by the clinical study.

Human epidemiological data suggest that EDC exposure during the perinatal period can negatively affect infant growth trajectory and neurodevelopment and possibly play an important role in the rapid epidemiological growth of obesity and diabetes. As an example, one study carried out in 460 mother-infant pairs from Korea showed that Mental and/or Psychomotor Developmental Indices of the Bayley Scales of Infant Development were inversely correlated in 6-month-old males with the maternal urinary levels of the phthalate metabolites MEHHP, MEOHP and MBP at the third trimester of pregnancy. Very recently, it was reported that mothers with overweight displayed increased levels of the highly persistent environmental chemicals polychlorinated biphenyls in breast milk 2-weeks postpartum and that there was a negative association between some of these compounds and the head circumference-for-age, weight-for-age, and weight-for-length z-scores of the infant at the age of 6 months.

However, there are discrepancies among findings, which can be attributed to differences in the temporal window of EDC exposure assessment (i.e., early versus late gestation or lactation), in the infants' age at which the measurements were carried out or to a misclassification of EDC exposure due to a single-point analyses of their exposure. In fact, one of the limitations of many epidemiological studies is the use of single spot urine samples at one time-point to estimate the exposure to EDCs. The limitation relies on the short biological half-lives of many of these chemicals and their quick excretion in urine, properties that cause a demand for multiple time point for a precise estimation of exposure assessment. Although different epidemiological studies have found an association between higher exposure to EDCs and neuroendocrine and neurodevelopmental alterations in toddlers and children, as far as we know, no clinical interventions have been carried out to elucidate whether reducing the exposure to EDCs can contribute to counteract/ameliorate these harmful effects.

So far, very few human intervention studies focused on reducing the exposure to EDCs during the perinatal period have been conducted, some carrying out educational approaches and others focused on dietary or other changes. Relevantly, most of them had small sample sizes (<100 people) and analysed a maximum of two different types of EDCs and quite a few were carried out without control groups. Moreover, the level of adherence in this type of interventions is low in general, reflecting the need to implement adequately behavioural change techniques to foster long-term lifestyle habit improvements. 2. Outcomes (efficacy, safety) Of completed and number of ongoing clinical studies utilizing the same intervention in the same indication (including review of public registers)

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Pregnant women with a viable pregnancy confirmed by ultrasound until 13 weeks and 0 days of gestation (recruitment between 6-11 weeks). Their partners will be invited to participate but this is not mandatory for inclusion.
  • •BMI at Visit 1 between 18.5-40 kg/m²
  • •Intention to breastfeed
  • •Being able to read the language of their respective countries (Dutch/French -Belgium-, Spanish and/or Catalan -Spain- and Polish -Poland)
  • •Being 18 years or older
  • •In possession of a smartphone. If participants do not have a smartphone because of socio-economic reasons, a smartphone will be at their disposal for the whole duration of the study

Exclusion Criteria

  • •Unable to sign informed consent (cultural barriers, psychological conditions)
  • •Abuse of substances (alcohol, drugs)
  • •Chronic use (at least, for three months before pregnancy) of any medication that might affect the HP axis:
  • •Antidepressants
  • •Insuline.
  • •Levothyroxine, Methimazole, Propylthiouracil.
  • •Oral corticosteroids (topical and inhalation formulations will be allowed)
  • •Arginine vasopressin (AVP)
  • •Mifepristone.
  • •Anticortisolic drugs: Metyrapone (Metopirone), Ketokonazole, Osilodrostat (Isturisa), Mitotane (Lysodren), aminoglutethimide (Cytadren) and Levoketoconazole (Recorlev).
  • •Multiple gestation
  • •Type 1 or 2 diabetes
  • •Pregnant women will not be consented into research by any HCP with whom they have a dependent relationship (Declaration of Helsinki) (I would remove this point).

Arms & Interventions

Behavioral intervention

Experimental

Healthy pregnant women who will receive a multi-component behavioral intervention (digital tool aimed at promoting lifestyle habits to reduce EDC exposure by providing personalized recommendations + telephone monitoring + workshops about environmental health education) during pregnancy and the first 18 months after delivery.

Intervention: Multi-Component Behavioral intervention (Behavioral)

Control group

Other

Healthy pregnant women who will receive the standard of care. The control condition consists of a single online education module/written information about EDCs addressed to reduce their exposure. They will also have access to the digital tool to answer the questionnaires, but this group will not receive any recommendations or missions from the professionals concerning EDCs along the study. After finishing the intervention, the participants of the control group will be offered access to all the developed material (workshops…) and to use the app.

Intervention: Control group (Behavioral)

Outcomes

Primary Outcomes

Decrease of mono(2-ethyl-5-oxohexyl) phthalate (MEOHP) concentration in urine

Time Frame: From first trimester of pregnancy to 18 months after delivery

This election was based on a scientific article in which was reported that mental and/or Psychomotor Developmental Indices of the Bayley Scales of Infant Development were inversely correlated in 6-month-old infants with the maternal urinary levels of MEHHP and MEOHP at the third trimester of pregnancy in a study carried out with 460 mother-infant pairs (4). However, since during the initial phase of the project a predictive modelling approach will be carried out in order to select the EDC mixtures with high harmful effects to be evaluated in preclinical models, the definitive main outcome could be redefined once we obtain the predictive modelling results. We would expect to detect a 25% decrease in the urinary levels of MEOHP in the intervention group vs control group at the end of the study.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Fundació Institut Germans Trias i Pujol
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials